Epsilogen specializes in developing immunoglobulin E (IgE) antibodies for cancer treatment, including the first therapeutic IgE antibody to enter clinical trials.

On Target Laboratories develops and commercializes FDA-approved imaging agents for cancer surgeries, using near-infrared dye and targeting molecules to aid in detecting and resecting cancer cells.

FORE Biotherapeutics is a precision oncology company that focuses on the clinical development of plixorafenib, a novel small-molecule inhibitor for treating BRAF-altered tumors.